Naloxone but not CCK-8 may attenuate binge-eating behavior in patients with the bulimia syndrome.
We undertook a study to see if putative anorectic agents could attenuate binge eating episodes in bulimic patients. Bolus intravenous administration, followed by continuous intravenous infusion of naloxone, resulted in a significant decrease in the amount of food consumed during binge-eating episodes, whereas bolus followed by continuous intravenous infusion of CCK-8 failed to significantly suppress binge eating behavior. These results suggest that the endogenous opioid system is involved in the maintenance of binge eating behavior in patients with bulimia.
D000328:Adult; D001067:Appetite Depressants; D002032:Bulimia / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D009270:Naloxone / Q000627:therapeutic use*; D012844:Sincalide / Q000627:therapeutic use*
D001067:Appetite Depressants; D009270:Naloxone; D012844:Sincalide